ANI PHARMACEUTICALS, INC Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
ANI PHARMACEUTICALS, INC (ANIP) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of -$30.28 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2025-11-07
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2024-12-31 was -$6.00K.
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2024-09-30 was -$30.27M.
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, equity component of convertible debt for fiscal 2024 was -$30.28M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$30.28M derived: sum of 2 quarters · filed 2025-11-07 | -$30.28M 10-K · filed 2025-02-28 | |||
| 2024-09-30 | -$30.27M 10-Q · filed 2025-11-07 | $30.27M 10-Q · filed 2024-11-08 | -$30.27M 10-Q · filed 2025-11-07 | $30.27M 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |